Physician profile
Reyadh Michail
NPI 1508847831
$7,999.40
in general payments reported to CMS, 2019-2025
48 companies · $2,090 in 2025
The $2,090 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $964 · 2020: $784 · 2021: $600 · 2022: $736 · 2023: $1,171 · 2024: $1,654 · 2025: $2,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,915.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,915.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,045.31 | 2019-2025 | Breztri, Airsupra, Fasenra |
| Amgen INC. | $958.75 | 2019-2025 | Evenity, Prolia, Prolia |
| Glaxosmithkline, LLC. | $708.46 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Teva Pharmaceuticals USA, INC. | $538.33 | 2020-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $424.94 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $393.07 | 2021-2025 | Rexulti, Nuedexta |
| Novartis Pharmaceuticals Corporation | $375.30 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $366.11 | 2019-2024 | Xifaxan, Trulance |
| Neurocrine Biosciences, INC. | $270.72 | 2022-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $195.64 | 2020-2022 | |
| Eisai INC. | $186.90 | 2021-2025 | |
| Ardelyx, INC. | $162.24 | 2024-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $143.05 | 2021-2025 | |
| Lilly USA, LLC | $140.90 | 2019-2025 | Jardiance, Emgality |
| Novo Nordisk INC | $122.17 | 2019-2024 | Rybelsus, Ozempic |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $117.71 | 2023-2025 | Gemtesa |
| Grifols USA, LLC | $116.58 | 2024-2025 | Prolastin-C Liquid |
| Amarin Pharma, INC. | $113.49 | 2019-2021 | |
| Radius Health, INC. | $112.84 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $111.80 | 2020-2025 | Capvaxive, Gardasil 9 |
| Sun Pharmaceutical Industries INC. | $108.23 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $98.95 | 2020-2022 | |
| Acadia Pharmaceuticals INC | $95.21 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $90.35 | 2022-2023 | Dupixent |
| Bioventus LLC | $87.98 | 2019-2024 | Supartz Fx Sodium Hyaluronate |
| Sanofi-Aventis U.S. LLC | $76.56 | 2020-2023 | |
| Allergan, INC. | $74.05 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $73.14 | 2025 | Zenpep |
| Lundbeck LLC | $66.47 | 2023-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.68 | 2025 | Caplyta |
| Exact Sciences Corporation | $58.36 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Gilead Sciences, INC. | $55.81 | 2025 | |
| Alexion Pharmaceuticals, INC. | $50.47 | 2022 | |
| Alkermes, INC. | $50.40 | 2023-2025 | Aristada, Lybalvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.26 | 2023-2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $46.75 | 2019 | |
| Genentech USA, INC. | $41.28 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $34.97 | 2024-2025 | |
| Arbor Pharmaceuticals, INC. | $22.83 | 2019 | |
| Depuy Synthes Sales INC. | $21.08 | 2025 | Orthovisc |
| Phathom Pharmaceuticals, INC. | $18.96 | 2024 | Voquezna |
| Smith+Nephew, INC. | $18.19 | 2022 | |
| Esperion Therapeutics, INC. | $17.83 | 2025 | Nexletol |
| Dexcom, INC. | $17.68 | 2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $17.22 | 2020 | |
| Astellas Pharma US INC | $16.47 | 2022 | |
| Pfizer INC. | $15.41 | 2019 | |
| Xeris Pharmaceuticals, INC. | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reyadh Michail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.